Arvinas (ARVN) Treasury Shares (2017 - 2026)

Arvinas (ARVN) posted quarterly Treasury Shares of $10.0 million for Q1 2026, little changed quarter-over-quarter from $10.0 million in Q4 2025.

Arvinas (ARVN) Treasury Shares (2017 - 2026) Analysis & Trends

Arvinas' Treasury Shares history runs 10 years deep, the most recent figure standing at $10.0 million for Q1 2026.

In Q1 2026, Treasury Shares changed N/A year-over-year to $10.0 million; the TTM figure through Mar 2026 stood at $10.0 million (changed N/A YoY), while the FY2025 annual figure was $10.0 million, changed N/A from the prior year.
Treasury Shares for Q1 2026 stood at $91.9 million, roughly flat from $91.9 million in the prior quarter.
The five-year high for Treasury Shares was $10.0 million in Q4 2025, with the low at $5929.0 in Q1 2022.
The 5-year median for Treasury Shares is $1.1 million (2023), against an average of $2.8 million.
The sharpest annual moves came in 2022 and 2023: Treasury Shares tumbled 96.55% in 2022, then surged 18575.56% in 2023.
Arvinas' Treasury Shares stood at $91.9 million in 2025, then changed by 0.0% to $91.9 million in 2026.
Business Quant data shows ARVN's Treasury Shares at $91.9 million in Q1 2026, $91.9 million in Q4 2025, and $20.3 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	5.08 Mn
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	2.72 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	92,219.00
10	Arvinas	585.74 Mn	17.84 Mn	-	10.00 Mn

Download Data